WEKO3
アイテム
{"_buckets": {"deposit": "39001a21-f563-4a3f-9db0-8fd10263a415"}, "_deposit": {"created_by": 11, "id": "3540", "owners": [11], "pid": {"revision_id": 0, "type": "depid", "value": "3540"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00003540", "sets": ["276"]}, "author_link": ["6858", "7892", "7890", "7891", "147"], "item_3_alternative_title_18": {"attribute_name": "その他の言語のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "HER2陽性乳癌に対してPertuzumabを用いた術前化学療法を施行した16例"}, {"subitem_alternative_title": "HER2 ヨウセイ ニュウガン ニ タイシテ Pertuzumab オ モチイタ ジュツゼン カガク リョウホウ オ セコウシタ 16レイ"}]}, "item_3_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-05-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "22", "bibliographicPageStart": "17", "bibliographicVolumeNumber": "33", "bibliographic_titles": [{"bibliographic_title": "滋賀医科大学雑誌"}]}]}, "item_3_creator_3": {"attribute_name": "著者別名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "阿部, 元"}], "nameIdentifiers": [{"nameIdentifier": "147", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "80283563", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=80283563"}]}, {"creatorNames": [{"creatorName": "寺本, 敦子"}], "nameIdentifiers": [{"nameIdentifier": "6858", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "竹井, 裕美子"}], "nameIdentifiers": [{"nameIdentifier": "7890", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "米田, 光里"}], "nameIdentifiers": [{"nameIdentifier": "7891", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "田中, 義人"}], "nameIdentifiers": [{"nameIdentifier": "7892", "nameIdentifierScheme": "WEKO"}]}]}, "item_3_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Pertuzumab is a molecular-targeted drug that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2) and inhibits dimer formation. The combined use of pertuzumab and trastuzumab for HER2-positive breast cancer has been reported to significantly increase the rate of pathological complete response (pCR) compared to that with trastuzumab monotherapy. We reported the outcomes of HER2-positive breast cancer treated with neoadjuvant chemotherapy with pertuzumab. Sixteen patients with stages II–III HER2-positive breast cancer were treated with 4 cycles of docetaxel (75 mg/m2) with trastuzumab and pertuzumab, followed by 4 cycles of 5-fluorouracil (500 mg/m2), epirubicin (100 mg/m2), and cyclophosphamide (500 mg/m2). The participants were in the age range of 45–76 years; T1, T2 and T3 stages were reported in 2, 11, and 3 cases, respectively, and N0 and N1 stages were reported in 6 and 10 cases, respectively. Luminal HER2 and HER2-enriched subtypes were noted in 8 cases each. In all cases, scheduled chemotherapy was completely implemented. Grade 3, 2b, 1a and 1b histology were observed in 11, 3, 1, and 1 cases, respectively. The rate of pCR (ypT0/is + ypN0) was 69%, whereas the objective response rate was 94%. In 12 cases, breast-conserving surgery was undertaken, whereas 4 patients underwent total mastectomy. Pertuzumab did not cause any complications, including cardiac dysfunction.", "subitem_description_type": "Abstract"}, {"subitem_description": "PertuzumabはHER2の細胞外ドメインに結合し、ダイマー形成を阻害するである。種々の試験において、trastuzumab単独よりもPertuzumabを併用した方が病理学的完全奏効率(pCR)を有意に上昇すると報告されている。今回、我々はHER2陽性乳癌に対してPertuzumabを用いた術前化学療法を行った。16名のStageII~IIIのHER2陽性乳患者に、Pertuzumab、Trastuzumab、Docetaxel(75 mg/m2)4コース、その後にFEC100療法4コースを施行した。年齢は45~76歳で、T1、T2、T3はそれぞれ2例、11例、3例、N0、N1はそれぞれ6例、10例であった。Luminal HER2 type、HER2 enrich typeともに8例であった。すべての症例で予定された化学療法が完全施行できた。組織学的効果はGrade3、2b、1a、1bがそれぞれ11例、3例、1例、1例であった。pCR(ypT0/is + ypN0)率は69%で、奏功率は94%であった。Pertuzumabによる心機能障害等の副作用は認められなかった。", "subitem_description_type": "Abstract"}]}, "item_3_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Departmental Bulletin Paper", "subitem_description_type": "Other"}]}, "item_3_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.14999/1521.00012662", "subitem_identifier_reg_type": "JaLC"}]}, "item_3_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "滋賀医科大学雑誌編集委員会"}]}, "item_3_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.14999/1521.00012662"}], "subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://doi.org/10.14999/1521.00012662", "subitem_relation_type_select": "DOI"}}]}, "item_3_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "ABE, Hajime"}], "nameIdentifiers": [{"nameIdentifier": "147", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "80283563", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=80283563"}]}, {"creatorNames": [{"creatorName": "TERAMOTO, Atsuko"}], "nameIdentifiers": [{"nameIdentifier": "6858", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TAKEI, Yumiko"}], "nameIdentifiers": [{"nameIdentifier": "7890", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YONEDA, Kohri"}], "nameIdentifiers": [{"nameIdentifier": "7891", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TANAKA, Yoshihito"}], "nameIdentifiers": [{"nameIdentifier": "7892", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-05-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "jsums3301p017.pdf", "filesize": [{"value": "551.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 551300.0, "url": {"label": "jsums3301p017", "url": "https://shiga-med.repo.nii.ac.jp/record/3540/files/jsums3301p017.pdf"}, "version_id": "6b54eada-81be-4fca-a169-0acf664509a5"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "HER2陽性乳癌", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pertuzumab", "subitem_subject_scheme": "Other"}, {"subitem_subject": "術前化学療法", "subitem_subject_scheme": "Other"}, {"subitem_subject": "pCR", "subitem_subject_scheme": "Other"}, {"subitem_subject": "HER2-positive breast cancer", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pertuzumab", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Neoadjuvant chemotherapy", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "pCR", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Sixteen cases of HER2-positive Breast Cancer treated with Neoadjuvant Chemotherapy with Pertuzumab.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Sixteen cases of HER2-positive Breast Cancer treated with Neoadjuvant Chemotherapy with Pertuzumab."}]}, "item_type_id": "3", "owner": "11", "path": ["276"], "permalink_uri": "https://doi.org/10.14999/1521.00012662", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-05-07"}, "publish_date": "2020-05-07", "publish_status": "0", "recid": "3540", "relation": {}, "relation_version_is_last": true, "title": ["Sixteen cases of HER2-positive Breast Cancer treated with Neoadjuvant Chemotherapy with Pertuzumab."], "weko_shared_id": -1}
Sixteen cases of HER2-positive Breast Cancer treated with Neoadjuvant Chemotherapy with Pertuzumab.
https://doi.org/10.14999/1521.00012662
https://doi.org/10.14999/1521.000126627374dbb1-661c-49dd-bdb9-bd1e7b96263a
名前 / ファイル | ライセンス | アクション |
---|---|---|
jsums3301p017 (551.3 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-05-07 | |||||
タイトル | ||||||
タイトル | Sixteen cases of HER2-positive Breast Cancer treated with Neoadjuvant Chemotherapy with Pertuzumab. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | HER2陽性乳癌 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Pertuzumab | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 術前化学療法 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | pCR | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | HER2-positive breast cancer | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Pertuzumab | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Neoadjuvant chemotherapy | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | pCR | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
ID登録 | ||||||
ID登録 | 10.14999/1521.00012662 | |||||
ID登録タイプ | JaLC | |||||
その他のタイトル | ||||||
その他のタイトル | HER2陽性乳癌に対してPertuzumabを用いた術前化学療法を施行した16例 | |||||
その他のタイトル | ||||||
その他のタイトル | HER2 ヨウセイ ニュウガン ニ タイシテ Pertuzumab オ モチイタ ジュツゼン カガク リョウホウ オ セコウシタ 16レイ | |||||
著者 |
ABE, Hajime
× ABE, Hajime× TERAMOTO, Atsuko× TAKEI, Yumiko× YONEDA, Kohri× TANAKA, Yoshihito |
|||||
著者別名 |
阿部, 元
× 阿部, 元× 寺本, 敦子× 竹井, 裕美子× 米田, 光里× 田中, 義人 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Pertuzumab is a molecular-targeted drug that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2) and inhibits dimer formation. The combined use of pertuzumab and trastuzumab for HER2-positive breast cancer has been reported to significantly increase the rate of pathological complete response (pCR) compared to that with trastuzumab monotherapy. We reported the outcomes of HER2-positive breast cancer treated with neoadjuvant chemotherapy with pertuzumab. Sixteen patients with stages II–III HER2-positive breast cancer were treated with 4 cycles of docetaxel (75 mg/m2) with trastuzumab and pertuzumab, followed by 4 cycles of 5-fluorouracil (500 mg/m2), epirubicin (100 mg/m2), and cyclophosphamide (500 mg/m2). The participants were in the age range of 45–76 years; T1, T2 and T3 stages were reported in 2, 11, and 3 cases, respectively, and N0 and N1 stages were reported in 6 and 10 cases, respectively. Luminal HER2 and HER2-enriched subtypes were noted in 8 cases each. In all cases, scheduled chemotherapy was completely implemented. Grade 3, 2b, 1a and 1b histology were observed in 11, 3, 1, and 1 cases, respectively. The rate of pCR (ypT0/is + ypN0) was 69%, whereas the objective response rate was 94%. In 12 cases, breast-conserving surgery was undertaken, whereas 4 patients underwent total mastectomy. Pertuzumab did not cause any complications, including cardiac dysfunction. | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | PertuzumabはHER2の細胞外ドメインに結合し、ダイマー形成を阻害するである。種々の試験において、trastuzumab単独よりもPertuzumabを併用した方が病理学的完全奏効率(pCR)を有意に上昇すると報告されている。今回、我々はHER2陽性乳癌に対してPertuzumabを用いた術前化学療法を行った。16名のStageII~IIIのHER2陽性乳患者に、Pertuzumab、Trastuzumab、Docetaxel(75 mg/m2)4コース、その後にFEC100療法4コースを施行した。年齢は45~76歳で、T1、T2、T3はそれぞれ2例、11例、3例、N0、N1はそれぞれ6例、10例であった。Luminal HER2 type、HER2 enrich typeともに8例であった。すべての症例で予定された化学療法が完全施行できた。組織学的効果はGrade3、2b、1a、1bがそれぞれ11例、3例、1例、1例であった。pCR(ypT0/is + ypN0)率は69%で、奏功率は94%であった。Pertuzumabによる心機能障害等の副作用は認められなかった。 | |||||
書誌情報 |
滋賀医科大学雑誌 巻 33, 号 1, p. 17-22, 発行日 2020-05-01 |
|||||
出版者 | ||||||
出版者 | 滋賀医科大学雑誌編集委員会 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | http://doi.org/10.14999/1521.00012662 | |||||
関連名称 | 10.14999/1521.00012662 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Departmental Bulletin Paper |